Immunovaccine Inc (IMV.TO)
1.85CAD
25 Apr 2018
$0.05 (+2.78%)
$1.80
$1.79
$1.85
$1.79
48,950
108,115
$2.55
$1.04
Latest Key Developments (Source: Significant Developments)
Immunovaccine Announces $12.5 Million Bought Deal Offering
Jan 25 (Reuters) - Immunovaccine Inc
Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Dec 5 (Reuters) - Immunovaccine Inc
Immunovaccine reports qtrly loss per share of $0.02
Nov 9 (Reuters) - Immunovaccine Inc
Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Nov 8 (Reuters) - Immunovaccine Inc
Immunovaccine Q2 loss per share C$0.02
Aug 8 (Reuters) - Immunovaccine Inc
Immunovaccine announces achievement in personalized cancer medicines
July 12 (Reuters) - Immunovaccine Inc
Immunovaccine announces $10 million bought deal offering
May 31 (Reuters) - Immunovaccine Inc
Immunovaccine says to initiate mid-stage trial of its blood cancer drug
May 16 (Reuters) - Immunovaccine Inc
Immunovaccine net loss, comprehensive loss of $2.4 mln for quarter ended March 31
May 10 (Reuters) - Immunovaccine Inc
Immunovaccine announces positive year-long immunogenicity data from phase 1 clinical trial for respiratory syncytial virus vaccine candidate
Immunovaccine Inc
BRIEF-Immunovaccine Announces $12.5 Million Bought Deal Offering
* IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE Source text for Eikon: Further company coverage: